A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
Details
Age
Adult
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Tejas Patil
Study ID
Protocol Number: 23-1245
More information available at ClinicalTrials.gov: NCT04844073
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers